Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-01-04
2011-01-04
Fetterolf, Brandon J (Department: 1628)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S557000
Reexamination Certificate
active
07863267
ABSTRACT:
The invention relates to methods of and treatments for using pharmaceutical compositions from a class of compounds that directly or indirectly selectively modulates GABAAchloride channel activity to treat alcohol and/or stimulant substance abuse. The present invention also relates to methods of, and protocols for, relieving symptoms associated with alcohol and/or stimulant substance abuse in a comprehensive treatment plan. More specifically, the present invention relates to the use of a selective chloride channel modulator, such as flumazenil, to treat alcohol and/or psychostimulant dependency, the withdrawal symptoms associated therewith, and the cravings associated therewith.
REFERENCES:
patent: 5028611 (1991-07-01), Halikas
patent: 5229120 (1993-07-01), DeVincent
patent: 5385903 (1995-01-01), Steppuhn et al.
patent: 5434156 (1995-07-01), Bjork et al.
patent: 5519017 (1996-05-01), Opitz
patent: 6346528 (2002-02-01), Yelle
patent: 6451783 (2002-09-01), Hadcock et al.
patent: 6541520 (2003-04-01), Dewey et al.
patent: 6593367 (2003-07-01), Dewey et al.
patent: 6890951 (2005-05-01), Dewey et al.
patent: 6906099 (2005-06-01), Dewey et al.
patent: 7186711 (2007-03-01), Ibanez
patent: 7348321 (2008-03-01), Ibanez
patent: 2002/0150632 (2002-10-01), Scott
patent: 2004/0162322 (2004-08-01), Rosenbaum
patent: 2005/0192271 (2005-09-01), Ibanez
patent: 2006/0167723 (2006-07-01), Berg
patent: 99/61014 (1999-05-01), None
patent: WO 2006/110557 (2006-10-01), None
patent: WO 2006/110580 (2006-10-01), None
patent: WO 2006/110642 (2006-10-01), None
Moy et al.; “Enhanced ultrasonic vocalization and Fos protein expression following ethanol withdrawal: effects of flumazenil”; 2000; Psychopharmacology; 105: 208-215.
Anglin et al.; “History of the methamphetamine problem”; 2000; Journal of Psychoactive Drugs; 32(2): 137-41.
Klotz, et al.; Pharmacokinetics and Clinical Use of Flumazenil; 1988; Clinical Pharmacokinetics; 14(1): 1-12.
Gerra et al.; “Intravenous flumazenil versus oxazepam tapering in the treatment of benzodiazepine withdrawl: a randomized, placebo-controlled study”; 2002; Addiction Biology; 7; 385-395.
Aguirre et al. Plasma b-endorphin levels in chronic alcoholics, Alcohol, vol. 7, pp. 409-412, 1990.
Derlet, Robert W. et al.; “Flumazenil Induces Seizures and Death in Mixed Cocaine-Diazepam Intoxications”; Annals of Emergency Medicine, vol. 23, No. 3, Mar. 1994, pp. 494-498.
Derlet, R.W. et al.; “Anticonvulsant Modification of Cocaine-Induced Toxicity in the Rat”; Neuropharmacology, vol. 29, No. 3, pp. 255-259, 1990.
Gasior et al. Chlormethiazole: Effectiveness against Toxic Effects of Cocaine in Mice. The Journal of Pharmacology and Experimental Therapeutics. vol. 295, No. 1, pp. 153-161. Oct., 2000.
Ito, Kouichi; “The Role of Gamma-aminobutyric Acid (GABA)-Benzodiazepine Neurotransmission in an Animal Model of Methamphetamine-Induced Psychosis”; Hokkaido J. Med Sci 74(2), pp. 135-144, 1999 (English Abstract Only).
Ito, K. “The Role of Benzodiazepine Receptors in the Acquisition and Expression of Behavioral Sensitization to Methamphetamine”; Pharmacology Biochemistry and Behavior, vol. 65, No. 4, pp. 705-710, 2000.
Malbrain et al.; “A Massive, Near-Fatal Cocaine Intoxication in a Body-Stuffer”; Acta Clinica Belgium 49.1 (1994), pp. 12-18.
Soderpalm et al. Benzodiazepines enhance the consumption and palatability of alcohol in the rat. Psychopharmacology, 1998, 137:215-222.
Uki, F. et al.; “The effect of flumazenil administration on acute cocaine intoxication of rats”; Arukoru Kenkyuto Yakubutsu Ison; Apr. 1994, 29(2):92-102 (Abstract only).
Woolf, Alan; “Cocaine Poisoning”; Clinical Toxicology Review, vol. 18, No. 8, May 1995; pp. 1-6.
Drug Facts and Comparsions 1997 Edition, pp. 3373-3379.
Non-final Office Action, U.S. Appl. No. 11/615,460, mailed May 13, 2010.
Final Office Action, U.S. Appl. No. 11/111,435, mailed Dec. 8, 2009.
Response and Request for Continued Examination, U.S. Appl. No. 11/11,435, filed Jun. 30, 2010.
Fetterolf Brandon J
Hythiam, Inc.
Kilpatrick & Stockton LLP
Thomas Timothy P
LandOfFree
Use of selective chloride channel modulators to treat... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of selective chloride channel modulators to treat..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of selective chloride channel modulators to treat... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2628962